Baillie Gifford & Co
RUBY

Baillie Gifford & Co’s Rubius Therapeutics, Inc RUBY Stock Holding History

Baillie Gifford & Co’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,869,126
Closed -$838K – 486
2022
Q4 		$838K Buy
4,869,126
+15,353
+0.3% +$4.19K ﹤0.01% 276
2022
Q3 		$2.1M Sell
4,853,773
-52,305
-1% -$39.2K ﹤0.01% 261
2022
Q2 		$4.17M Sell
4,906,078
-1,393
-0% -$2.34K ﹤0.01% 243
2022
Q1 		$27M Sell
4,907,471
-23,388
-0.5% -$149K 0.02% 196
2021
Q4 		$47.7M Buy
4,930,859
+237,027
+5% +$3.29M 0.03% 191
2021
Q3 		$83.9M Sell
4,693,832
-1,190
-0% -$25.9K 0.04% 151
2021
Q2 		$115M Buy
4,695,022
+1,151
+0% +$28.8K 0.06% 146
2021
Q1 		$124M Sell
4,693,871
-16,190
-0.3% -$236K 0.07% 139
2020
Q4 		$35.7M Buy
4,710,061
+436,200
+10% +$2.59M 0.02% 180
2020
Q3 		$21.4M Buy
4,273,861
+19,129
+0.4% +$101K 0.01% 180
2020
Q2 		$25.4M Sell
4,254,732
-2,168
-0.1% -$12.8K 0.02% 165
2020
Q1 		$18.9M Buy
4,256,900
+5,430
+0.1% +$40.3K 0.02% 148
2019
Q4 		$40.4M Buy
4,251,470
+10,703
+0.3% +$104K 0.04% 134
2019
Q3 		$33.3M Buy
4,240,767
+6,085
+0.1% +$70.9K 0.04% 141
2019
Q2 		$66.6M Buy
4,234,682
+101,831
+2% +$1.64M 0.07% 112
2019
Q1 		$74.8M Buy
4,132,851
+76,655
+2% +$1.18M 0.08% 108
2018
Q4 		$65.2M Buy
4,056,196
+146,584
+4% +$2.67M 0.08% 106
2018
Q3 		$93.8M Buy
+3,909,612
New +$89.4M 0.1% 96

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Baillie Gifford & Co's RUBY Position: Q1 2023 in Review

Baillie Gifford & Co sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 4,869,126 shares — an estimated $838K sold.

Baillie Gifford & Co first reported a position in RUBY in Q3 2018 and held it in 18 quarters. The position peaked at $124M in Q1 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Baillie Gifford & Co reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 4,869,126 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $838K.
  • Baillie Gifford & Co first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 18 quarters.
  • Baillie Gifford & Co's Rubius Therapeutics, Inc position peaked at $124M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Baillie Gifford & Co's 13F filing for Q1 2023, filed 3 May 2023.